Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Completed · Phase 3
Conditions studied: Bardet-Biedl Syndrome, POMC Deficiency
In brief
A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.
Key facts
- Study ID
- NCT05194124
- Run by
- Rhythm Pharmaceuticals, Inc.
- People needed
- 19
- Starts
- 2021-12-21
- Expected to finish
- 2023-10-19
- Last updated by the study team
- 2024-11-26
Who can join
Age: 6 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Honor Health Research Institute — Scottsdale, Arizona, United States
- Marshfield Clinic Research Institute — Marshfield, Wisconsin, United States
- Alberta Health Services — Edmonton, Alberta, Canada
- Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum — Berlin, Germany
- Erasmus MC — Rotterdam, Netherlands
- UPR Medical Sciences Campus — Rio Piedras, Puerto Rico
- Addenbrooke's Hospital — Cambridge, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.